Skip to main
HOTH
HOTH logo

Hoth Therapeutics (HOTH) Stock Forecast & Price Target

Hoth Therapeutics (HOTH) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Hoth Therapeutics Inc. has demonstrated a robust potential for growth, as evidenced by the 100% efficacy seen in its Phase 2a CLEER-001 trial evaluating HT-001, which significantly reduced skin toxicity and enhanced quality of life for cancer patients undergoing treatment. The company is strategically positioned to facilitate clinical adoption through extensive real-world exposure of its therapies, which may strengthen its regulatory standing and enhance engagement with key stakeholders such as oncologists and patient advocacy groups. Furthermore, the promising results from open-label trials and case studies related to various therapies underscore Hoth's diverse pipeline addressing significant unmet medical needs, supporting a favorable outlook for its financial performance and market positioning.

Bears say

Hoth Therapeutics Inc. operates in a highly competitive and uncertain biopharmaceutical landscape, with several clinical trials ongoing that may not yield successful results, which raises concerns regarding the company's ability to advance its pipeline products. Financial data indicates high burn rates associated with research and development, creating potential liquidity issues if funding sources diminish or fail to meet expected needs. The company's reliance on unproven therapies for various conditions, coupled with the regulatory and market risks inherent in the sector, contributes to a challenging environment that could impede growth and profitability.

Hoth Therapeutics (HOTH) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hoth Therapeutics (HOTH) Forecast

Analysts have given Hoth Therapeutics (HOTH) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Hoth Therapeutics (HOTH) has a Strong Buy consensus rating as of Jun 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hoth Therapeutics (HOTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.